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A B S T R A C T 
 
Aim: Since HER2-targeted therapies have shown clinical benefit in breast cancer, in the present study 
recombinant baculovirus (BV) displaying anti-HER2 scFv expressing Apoptin was generated. 
Methods: The binding specificity and surface display of anti-HER2 scFv were evaluated using 
ELISA and electron microscopy, respectively. The targeting properties and cytotoxic effect on breast 
cancer cells determined by fluorescence microscopy and MTT assays. Results: The results 
demonstrated that recombinant BV could specifically bind to HER2-overexpressing SK-BR-3 cells 
but not to the HER2 negative MCF-7 cells and reduced the viability of SK-BR-3 cells by expressing 
Apoptin. Conclusion: These results suggest that the antitumor effect of Apoptin in combination with 
HER2 targeting of this recombinant BV makes it a promising vector in targeted cancer therapy. 
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Introduction 
 
Breast cancer is the most common type of cancer in women and its prevalence has increased by 
approximately 40% worldwide during the past 25 years[1]. Although conventional therapies in breast 
cancer such as surgery, chemotherapy, radiotherapy and hormone therapy treatments are beneficial for 
suppressing the tumor growth, their low tumor selectivity and high toxicity of these treatments 
highlights a need for the research and development of improved, cancer-selective therapeutics. 
Targeted therapy due to the minimizing the side effects has become increasingly interesting for cancer 
treatments [1-3]. 
Human epidermal growth factor receptor-2 (HER2) is a transmembrane tyrosine kinase receptor 
which is highly expressed in 25-30% of all breast cancer cases and is associated with poor prognosis 
and aggressive tumor phenotypes. HER2 overexpression and its extracellular domain accessibility 
make it a valuable target for receptor-mediated, targeted drug delivery systems in cancer therapy [4]. 
The humanized monoclonal antibody trastuzumab (Herceptin™), which is used for treatment of 
cancer cells overexpressing HER2, is one of the most promising drugs in breast cancer therapy. 
Despite increases in cell death via various mechanisms and prolonged survival of patients with HER2-
overexpressing breast cancers by treated with trastuzumab, it showed moderate potency, toxic side-
effects and drug resistance in 66–88% of patients. Therefore, additional therapies are needed [5, 6]. 
  
Gene therapy has provided potential treatments for a number of different diseases which are difficult 
to treat by conventional therapy. Among different systems in gene therapy, viral vectors have become 
important tools to introduce therapeutic genes into the cells. Baculoviral vectors derived from the 
insect Autographa californica multiple nucleopolyhedrovirus (AcMNPV) virus of the baculovirus 
(BV) family which carries mammalian cell active promoters has shown to be able to mediate gene 
transfer to a broad range of mammalian cell types. Although baculovirus vectors have not yet been 
used as a gene therapy agents in clinical practice, they have demonstrated promising potential in 
various preclinical studies for a variety of therapeutic applications including cancer treatment, tissue 
engineering, and vaccination [7]. In contrast to human viral vectors such as retroviruses, adenoviruses, 
and adeno-associated viruses, baculoviruses cannot replicate in mammalian cells and there is no 
detectable immune responses to BV in humans [7, 8]. Furthermore, their large cloning capacity (38 
kb), easy manipulation, high recombinant viral titers and minimal cytotoxicity, all make this vector 
highly attractive for cancer gene therapy [9-11]. Also, baculovirus display technology has been used 
for presentation of foreign proteins on the recombinant BV, GP64 envelope glycoprotein for different 
therapeutic applications. For instance, a BV vector displaying scFv (single-chain variable domain 
fragment) specific CEA (carcinoembryonic antigen) to GP64 demonstrated binding specificity to 
CEA-expressing cells. However, the fusion to GP64 restricts the display to the poles of the virions, 
therefore other strategies for BVs display have been proposed [12] [13].  
 
ScFvs comprised of the variable heavy domain (VH) and the variable light domain (VL) are the 
smallest functional antigen-binding domain of an antibody [4, 14]. Due to their low cost, easy 
production, faster blood clearance and better tumor penetration in comparison with full-length 
antibodies, they have many advantages as potential therapeutics for several diseases, including HIV, 
cancer and neurodegenerative diseases. Therefore, they are more favourable for targeting specific 
markers on tumor cells by viral vector in drug delivery systems [15, 16].  
 
Combination therapy by the monoclonal antibody which mediated targeting of cancer cells with an 
optimized cytotoxic effector is a promising strategy for treatment of HER2-positive tumors, due to the 
reducing the damage to normal tissues [17]. 
 
Modulation of apoptosis is a powerful tool in cancer therapy. Apoptin (VP3) is an anti-cancer protein 
derived from chicken anemia virus (CAV) that induces the selective death in different cancer cell 
lines but not in normal cells. Apoptin tumor -specificity is associated with its ability to localize in the 
nuclei of transforming cells, whereas it is mainly found in the cytoplasm of normal cells [14, 18-20]. 
However, the precise mechanisms of Apoptin-induced cell death remainsremain unclear, though it has 
been proposed that Apoptin induces apoptosis by phosphorylation atwhen phosphorylated at threonine 
108 of by Apoptin-specific kinases in tumor cells[21]. Moreover, phosphorylated Nur77, a nuclear 
orphan receptor, can be relocated from the nucleus to the cytoplasm upon transient expression of 
Apoptin and it regulates the binding of Nur77 to the anti-apoptotic protein Bcl-2 which triggers the 
p53-independent mitochondrial death pathway [22]. Numerous studies have reported that recombinant 
adenoviruses, poxviruses and parvoviruses expressing Apoptin had significant antitumor activity in 
vivo [23]. Therefore, these advantages make Apoptin an attractive agent for selective anticancer 
therapy.  
Baculoviruses expressing Apoptin have been studied in human hepatocarcinoma cells (HepG2) [9], 
but there is no study on the baculovirus expressing Apoptin in breast cancer cells. Therefore, we 
aimedthe aim was to develop a dual function recombinant baculovirus displaying anti-HER2 scFv 
expressing Apoptin which specifically targets HER2-positive breast cancer cell lines by anti-HER2 
scFv which also displays a cytotoxic effect via Apoptin.  
 
 
Materials and methodsMethods 
 
 Cell lines and cultures 
 
SK-BR-3 (high HER-2 expression), MCF-7 (low HER-2 expression) CHO (Chinese hamster ovary 
cells) and HEK-293 (human embryonic kidney cells) cell lines were obtained from the Iranian 
Biological Resources Centre (IBRC) [24]. Cells were grown at 37 ˚C with 5% CO2 in Dulbecco 
Modified Eagle Medium (DMEM) (Gibco, USA) containing 10% fetal bovine serum (Gibco, USA), 
1% L-glutamine (Gibco, USA), 100 U/mL penicillin and 100 μg/mL streptomycin. The insect cell line, 
Sf9, were was purchased from IBRC and maintained in serum-free medium SF-900 III (Invitrogen, 
USA) supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin at 27 ˚C. 
 Construction of recombinant baculoviruses vectors 
 
Recombinant baculovirus vectors were constructed according to Invitrogen’s Bac-to-Bac baculovirus 
expression system. Briefly, the anti-HER2 scFv was designed according to the amino acid sequences 
of the variable heavy (VH) and light (VL) regions of trastuzumab containing the 18 amino acids 
(MEASLAAQAAQIQLVQSG) of the scFvE2/p17 sequence (epitope of the matrix protein (MAp17) 
of HIV-1) and HA tag (hemagglutinin epitope of Influenza A virus), YPYDVPDYA, in the N and C-
terminal, respectively [13]. The vector containing the synthesized anti-HER2 scFv (Genscript (China) 
was subcloned into the transfer plasmid pFastBac1 (Invitrogen, USA) at BamHI and EcoRI sites to 
generate anti-HER2 scFv pFastBac1. CMV (cytomegalovirus immediate-early promoter) and the 
EGFP (the enhanced green fluorescent protein) reporter gene were amplified from vector pEGFP-C1 
(BD Biosciences, USA)  andUSA) and sub cloned into the anti-HER2 scFv pFastBac1 at SnaBI site 
and into the plasmid pFastBac1 at BamHI and EcoRI sites to produce the PCMV-EGFP anti-HER2 
scFv pFastBac1 and PCMV-EGFP pFastBac1(BV-control), respectively. 
 
To generate a recombinant baculovirus expressing Apoptin, the Apoptin gene was commercially 
synthesized based on the sequences in GenBank (NC-001427) in pBSK (+) Simple-Amp plasmid by 
Biomatik (Canada), then the full-length Apoptin gene was amplified by PCR amplification using 
primers contacting containing the NheI & SmaI restriction sites and subcloned into the PCMV-EGFP 
anti-HER2 scFv pFastBac1 plasmid to create the PCMV-Apoptin anti-HER2 scFv pFastBac1. 
Subsequently, competent DH10Bac E. coli cells were transformed with the recombinant plasmids 
PCMV-EGFP anti-HER2 scFv pFastBac1, PCMV-Apoptin anti-HER2 scFv pFastBac1, and PCMV-
EGFP pFastBac1. After selecting colonies through the white/blue selection and PCR with the M13 
forward and reverse primers, recombinant bacmids DNA were isolated from white colonies according 
to the Bbac-to-bac Bac (Invitrogen) procedure. All primers used for cloning and confirmation showed 
in the Supplementary Table 1. 
 
 Recombinant Baculovirus production and purification 
 
For production of recombinant baculoviruses, Sf9 cells were transfected by the recombinant bacmids 
DNA with CellFectin II reagent (Invitrogen, USA) in 6-well plates at a density of 8 × 105, according 
to manufacturer’s instructions. The supernatant containing recombinant viruses was harvested after 6 
days post-transfection and used for large scale viral production. Therefore, Sf9-III cells were infected 
at 0.01 MOI in T75 flasks and the supernatant was collected at four days post-infection. The 
recombinant viruses were purified by sucrose gradient ultracentrifugation according to the following 
protocols.  
The supernatants of infected Sf9 cell culture were harvested at 96 hours post-infection and clarified by 
centrifugation at 1500 rpm in 4˚C for 15 min. For electron microscopy, BV particles were further 
purified by ultracentrifugation at 27000 rpm for 75 minutes at 4˚C through a 1ml sucrose cushion 
(20% sucrose in PBS) (Beckman Ultracentrifuge). The purified baculoviral pellet was resuspended in 
PBS overnight at 4˚C and the titers of BV suspensions determined by a plaque assay. (Bac-to-Bac 
Invitrogen) 
 
 Expression of the anti-HER2 scFv in Sf9 cells  
 
Western blotting was used to confirm the expression of the anti-HER2 scFv protein in Sf9 cells. Sf9 
cells were seeded in 6-well plates at a density of 6 × 105 cells per well. After 5 hours, cells were 
transfected with recombinant baculoviruses at an MOI of 2. Four days later, Sf9 cells were lysed 
using I-PER Insect cell protein extraction buffer containing protease inhibitor (Thermo Scientific). 
Cell lysates were centrifuged at 14000 rpm for 10 min at 4˚C and protein in the supernatants used for 
western blotting. Sixty micrograms of each sample, after being heat-denatured for 5 minutes, were 
loaded into SDS polyacrylamide gel. After migration, proteins were transferred to polyvinylidene 
difluoride (PVDF) membrane and then treated with an anti-HA mouse monoclonal antibody at a 
concentration of 1:4000 in 3% BSA/TBST (Sigma, USA) as primary antibodies. Goat anti-mouse 
immunoglobulin conjugated to horseradish peroxidase (170-6516, Bio-Rad, USA) diluted 1:5000 in 
3% BSA/TBST was used as the secondary antibody for detection of the primary antibodies. The 
protein bands were detected with via ECL (Cyto Matin Gene, Iran) according to the manufacturer’s 
guidelines. 
 
 
 Indirect ELISA 
 
The functionality of recombinant anti-HER2 scFv was evaluated by their binding activity to the 
recombinant extracellular region of HER2 (HER2-ECD) antigen [25] (SinaBiotech Co, Tehran, Iran), 
invia a standard indirect ELISA procedure. In brief, 50 μl of recombinant HER2-ECD antigen 
solution at 2 μg/ml in PBS buffer (pH 7.5) were was incubated overnight at 4˚C in 96-well plates. The 
coated wells were blocked with 50 μl of blocking buffer (1% BSA in PBS) for 1.5 hours h and a half 
at 37˚C, then washed three times with washing buffer (0.05% Tween-20 in PBS). 50 μl of purified 
anti-HER2 scFv-BV and EGFP-BV at dilutions of 1:1000 were added to each well and incubated for 
1 hr at 37˚C. After three times of washing, monoclonal anti-HA tag antibody (Sigma, USA) was 
added at a dilution of 1:2000 in 1% BSA-PBS, and incubated for 1 hr 37˚C. After three washes, wells 
were further incubated with 50 μl of Goat anti-mouse antibody conjugated to HRP (Bio-Rad, USA) 
diluted 1:3000 in 1% BSA-PBS and incubated for 1 hr 37˚C. Then 50 μl of TMB solution was added 
to each well. Finally, the reaction was stopped by addition of 50 μl of 10% sulfuric acid and the 
absorbance measured by using an ELISA plate reader at 450 nm. 
 
 Sandwich ELISA  
 
The binding specificity of the anti-HER2 scFv expressing on the surface of recombinant baculovirus 
was determined by a sandwich ELISA. 50 μl of purified BV-PCMV-EGFP anti-HER2 scFv and BV-
control at dilutions of 1:1000 in carbonate buffer (pH 9.6), were added to each well and incubated 
overnight at 4 ˚C in 96-well plates. The coated wells were blocked with 50 μl of blocking buffer (1% 
BSA in PBS) for 1.5 hours at 37 ˚C and washed three times with washing buffer (0.05% Tween-20 in 
PBS). Then 50 μl of recombinant HER2-ECD antigen solution at 2 μg/ml in PBS added to each well 
and incubated for 1 hr at 37 ˚C. After washing the wells, 50 μl of HRP conjugated anti-HER2 
monoclonal antibody (1T0 mAb), which recognizes different epitopes to trastuzumab [26], was added 
to each well and incubated for 1 hr at 37 ˚C. Following a final wash, TMB substrate was added to 
each well and absorbance read at 450 nm. 
 
 
  Indirect Immunofluorescence Assay 
 
To confirm the expression of anti-HER2 scFv protein an indirect immunofluorescence assay was 
performed. At 72h post-infection Sf9 cells were washed with PBS and fixed by methanol/acetone (1:1) 
for 10 minutes at room temperature (RT), then permeabilized in 5% Triton X-100 and washed with 
PBS.  The cells were subsequently incubated with the primary antibody anti-HA (1:1000 in 1% PBS-
BSA) (Sigma, USA) for 1 hour at 37˚C, followed by three PBS washes and then incubated with the 
secondary antibody Alexa Fluor 488-conjugated anti-mouse IgG (1:200 dilution in PBS-BSA) 
(Abcam, Hong Kong) for 1 hour at 37 ˚C. After this, wells were washed three times with PBS, 
followed by three PBS and visualized under fluorescence microscope (Olympus, Japan). We used 
PBS and BV-control were used as negative controls. 
 
 Electron Microscopy (EM) 
 
In order to confirm the expression of anti-HER2 scFv on the surface of the recombinant baculovirus 
electron microscopy was performed. The carbon-coated grids were covered by 20 µl purified 
baculovirus for 30 minutes. Then grids were incubated with primary antibody anti-HA tag 
monoclonal antibody at a dilution of 1: 1000 in 1% PBS-BSA (Sigma, USA) for 1 hour at RT. After 
washing with PBS three times for 5 minutes, the grids were incubated with 10 nm gold-tagged goat 
anti-mouse IgG antibody at a dilution of 1: 100 in 1% PBS-BSA (Sigma, USA) for 30 minutes at RT 
in dark. After three PBS washes, the grids were negatively stained with 1% uranyl acetate in H20 for 
10 min at RT, washed again with PBS, and examined under electron microscopy (LEO 906 Electron 
microscope (Zeiss, Germany). 
 
 Recombinant baculovirus infection into human breast cancer cell lines 
 
  Fluorescence microscopy 
 
Breast cancer cell lines, including SK-BR-3 and MCF-7 were cultured in 6-well plates. For following 
the specific targeting of HER2-positive breast cancer, cells were infected with recombinant BV 
carrying PCMV-EGFP anti-HER2 scFv, or BV-control at an indicated MOI for 4 hours at 27˚C. After 
removal of the viruses, fresh medium was added and incubated at 37˚C. 24, 48, and 72 hours post 
infection cells were observed using a fluorescence microscopy (Olympus, Japan). 
 
 Assessing Apoptin expression by western blot  
 
Western blotting was used to confirm the expression of the Apoptin protein. Briefly, SK-BR-3 and 
MCF-7 breast cancer cells were seeded in 6-well plates at a density of 5 × 105 cells per well. After 24 
h, cells were transfected with recombinant BV PCMV-Apoptin anti-HER2 scFv and BV-control at an 
MOI of 100. Forty-eight48  hours later, cells were lysed in ice-cold RIPA buffer (0.1% SDS, 150 mM 
NaCl, 50 mM Tris-HCl, 0.1% Triton-X100, 0.5% sodium deoxycholate and protease inhibitor). Cell 
lysates were centrifuged and protein in the supernatants were used to load into SDS polyacrylamide 
gel. Rabbit anti-Apoptin (Abcam ab193612; diluted 1:5000 in 3% BSA/TBST) and mouse anti-β-
Actin (Sigma T5168; diluted 1:2,500 in 3% BSA/TBST) were used as primary antibodies. HRP-
conjugated goat anti-rabbit secondary antibody and HRP-conjugated goat anti-mouse secondary 
antibody (Sigma, USA) were used at 1:6000 dilution. Western blotting was carried out as previously 
described. Beta-Actin protein was used as endogenous reference. Proteins were detected with the ECL 
western blotting detection system. 
 
  In vitro cytotoxicity of baculovirus expressing Apoptin in breast cancer cell lines 
 
Cytotoxicity assessment of the recombinant baculovirus carrying Apoptin (BV-PCMV-Apoptin anti-
HER2 scFv) carried outwas performed in SK-BR-3 and MCF-7 cells using MTT assays (a tetrazolium 
dye, 3-[4, 5-dimethylthiazol-2-yl]-2, 5- diphenyltetrazolium bromide; thiazolyl blue). Briefly, SKBR3 
and MCF-7 cells were seeded in 96-well plates at a density of 1 × 104 cells and after 24 hours, cells 
were incubated with the recombinant baculovirus at different MOI (50 and 100), and baculovirus 
control MOI 100. At 24 and 48 hours post-infection, cell viability was measured by MTT assay kit 
(BIO-IDEA, Iran) according to the manufacturer’s instructions. Three independent experiments were 
performed and finally, the absorbance at 570 nm was measured. 
 
 
 Statistical analysis 
 
Student’s t-test was used for statistical analysis.  Results were expressed as mean ± standard deviation 
(SD), and represent data from three independent experiments. P-value ≤ 0.05, ≤ 0.01 and ≤ 0.001 were 
considered significant and are represented by an asterisk *, **, and ***, respectively. 
 
 
Results 
 Construction and production of recombinant baculovirus  
 
To construct recombinant baculovirus vectors according to the Bac-to-Bac Invitrogen technology, the 
anti-HER2 scFv containing the 18 amino acids (MEASLAAQAAQIQLVQSG) sequence in the N- 
terminal for displaying the anti-HER2 scFv on the BV’s envelope, and containing an HA tag at the C-
terminal to detect the expressed protein by HA-tag monoclonal antibody in western blotting and 
immunofluorescence, were cloned into the plasmid pFastBac1. Then CMV promoter and EGFP were 
amplified from the vector pEGFP-C1 and sub cloned into the anti-HER2 scFv pFastBac1 and into the 
plasmid pFastBac1 to produce the PCMV-EGFP anti-HER2 scFv pFastBac1 and PCMV-EGFP 
pFastBac1, respectively. PCMV-EGFP anti-HER2 scFv pFastBac1 were transfected into CHO and 
HEK-293 cell lines to confirm the EGFP expression (Supplementary Figure 1a, b). 
 To generate a recombinant baculovirus expressing Apoptin, the Apoptin gene was subcloned into the 
PCMV-EGFP anti-HER2 scFv pFastBac1 plasmid which was constructed in the previous process to 
create the PCMV-Apoptin anti-HER2 scFv pFastBac1. The structures of the engineered recombinant 
BVs in this study are shown in Figure 1(A-C). Subsequently, competent DH10Bac E. coli cells were 
transformed with the recombinant pFastBac1plasmids to produce the recombinant bacmids. After 
selecting colonies through the white/blue selection, the production of recombinant bacmids DNA was 
confirmed by PCR with the M13 forward and reverse primers (Supplementary Figure 2). 
 
In order to produce the recombinant baculoviruses, Sf9 cells were transfected by the recombinant 
bacmids. The viral particles were produced in Sf9 cells at 96 hours post-transfection, CPE in 
transfected Sf9 cells was confirmed by observation ofby increasing increased in size and rounding up 
was observed in the transfected cells (Figure 1D) compared to the controls (Figure 1E). The 
recombinant viruses were purified by sucrose gradient ultracentrifugation and the titers of BV 
suspensions were determined by plaque assay. The titers of the purified viruses were 1.6 × 107 
PFU/ml for BV-control, 1.8 × 108 PFU/ml for BV-PCMV-EGFP anti-HER2 scFv and 1.5 × 107 
PFU/ml for BV- PCMV-Apoptin anti-HER2 scFv. 
 
 
 Expression of anti-HER2 scFv in Sf9 cells  
 
The expression of the anti-HER2 scFv in Sf9 cells was confirmed by western blotting analysis using 
mouse anti-HA-tag monoclonal antibody and horseradish peroxidase labelled goat anti-mouse IgG. 
The results showed that anti-HER2 scFv protein with a molecular weight of 30 kDa was expressed by 
recombinant BV-PCMV-EGFP anti-HER2 scFv and BV- PCMV-Apoptin anti-HER2 scFv in 
transfected cells but not in BV-Control and non-transfected Sf9 cells after 96 hours post- infection 
(Figure 2). 
 
 
 Immunological functionality and specificity of anti-HER2 scFv displayed on the baculovirus 
envelope 
 
Efficient display of functional anti-HER2 scFv on the BV surface was confirmed by Indirect ELISA 
using a recombinant extracellular region of HER2 (HER2-ECD) antigen. In this assay, recombinant 
HER2-ECD antigen was coated in the wells of the plate, then purified BV virions was were added to 
each well and probed with monoclonal anti-HA tag antibody. The positive reaction indicated 
significanttly the binding of a specific epitope of the HER2-ECD antigen to the anti-HER2 scFv 
displayed on the baculovirus envelope (p-value= 0.0015) and also confirmsed that the c-terminal 
region of anti-HER2 scFv was exposed at the surface of the BV. No binding of antibodies to controls 
were observed. (Figure 3A) 
 
The Sandwich ELISAs were designed to assess the binding specificity and accessibility of anti-HER2 
scFv antigen-binding regions. BV-PCMV-EGFP anti-HER2 scFv and BV control virions were 
immobilized on an ELISA plate and incubated with recombinant HER2-ECD antigen, then probed 
with HRP- conjugated anti-HER2 monoclonal antibody which recognize different epitopes than 
trastuzumab. The result shows that BV-PCMV-EGFP anti-HER2 scFv significantly reacted with 
recombinant HER2-ECD antigen in compare withcompared to controls (p-value 0.02) (Figure 3B). 
 
 
 Indirect Immunofluorescence analysis of BV- displayed anti-HER2 scFv  
 
BV-infected Sf9 cells were harvested at 72 hours post- infection and examined in via 
immunofluorescence microscopy using anti-HA tag antibody. Immunofluorescence analysis of the 
BV-displayed anti-HER2 scFv showed that anti-HER2 scFv expressed on the BV and the C-terminal 
HA tag was oriented outwards (Figure 4A) in compare withcompared to the negative controls of PBS 
and BV-control as a negative control (Figure 4B, 4C). 
 
 
 Immuno-Electron Microscopy of baculovirus displaying anti-HER2 scFv 
 
In order to confirm the reality of surface expression of anti-HER2 scFv on the recombinant 
baculovirus, the carbon-coated grids were covered by purified baculovirus and incubated with 
immune gold-labelled anti-HA tag antibody`, observed under the electron microscope. The result 
demonstrated that gold particles attached to the surface of recombinant BV-displayed anti-HER2 scFv 
(Figure 5A). In contrast, no gold anti-HA labelling were detected on the surface of BV-control virions 
(Figure 5C5B). 
 
 
 Selective targeting of BV-displaying anti-HER2 scFv selectively targets the HER2 positive 
SK-BR-3 breast cancer cells 
 
The targeting property properties of BV-displaying anti-HER2 scFv against HER2-positive breast 
cancer cells were determined by evaluating EGFP expression under the fluorescence microscopy 
using the human breast cancer cell lines SK-BR-3 and MCF-7 which exhibit high and low HER-2 
expression, respectively (25). Breast cancer cells were infected with recombinant BV-PCMV-EGFP 
anti-HER2 scFv at different MOIs 50,100,200, and BV-control at MOI 100 at 24, 48, and 72 hours 
post- infection. 
As shown in Figure 6 BV-displaying anti-HER2 scFv could specifically bind to SK-BR-3 cells and 
expressed EGFP in a dose- dependent manner in compared withcompared to no fluorescence 
detection on BV-Control and MCF-7 cell lines. 
 
 
 Apoptin expression in breast cancer cells of determined by western blot  
 
Western blot analysis was performed to determine whether the Apoptin protein was expressed in the 
SK-BR-3 and MCF-7 breast cancer cells after infection with recombinant BV-PCMV-Apoptin anti-
HER2 scFv at an MOI of 100 at 48 hours post-infection. As shown in Figure 7, a band corresponding 
to a molecular weight of about approximately 40 kDa was detected in the cell lysates of BV-PCMV-
Apoptin anti-HER2 scFv transduced cells but not in the cell lysates of BV-control transduced cells. 
The results demonstrated low level of Apoptin expression in MCF-7 cell line in compared with SK-
BR-3 cell lines (p-value= 0.00017).  
 
 
 BV-displaying anti-HER2 scFv Apoptin cytotoxicity is selectively cytotoxic to SK-BR-3 
HER-2 positive breast cancer cells 
 
Cytotoxic effects of BV anti-HER2 scFv expressing Apoptin, in SK-BR-3 and MCF-7 breast cancer 
cell lines was measured by MTT assays. The results showed that BV anti-HER2 scFv expressing 
Apoptin significantly reduced the cell viability of SK-BR-3 HER-2 positive breast cancer cell lines in 
compare withcompared to MCF-7 cells at 24 and 48 hours post- infection (Pp-value 0.016 and 0.006, 
respectively) at an MOI 50 in a time-dependent manner. In addition, BV anti-HER2 scFv expressing 
Apoptin decreased the cell viability of SK-BR-3 cell lines 20.6% and 25.3% in compare with 
compared to MCF-7 cells at 24 and 48 hours post- infection at an MOI 100. In contrast, when cells 
were treated with BV anti-HER2 scFv and BV-Control there was no significant difference in the cell 
viability of the MCF-7 and SK-BR-3 cells. These data indicated that BV anti-HER2 scFv expressing 
Apoptin specifically killed SK-BR-3 HER-2 breast cancer cells while it had low or no toxicity in 
MCF-7 breast cancer cells. (Figure 8A, 8B). All samples normalizes with BV-controls. 
 
 
Discussion 
Targeted cancer therapy is becoming important due to its specificity towards cancer cells whereas 
whilst leaving normal cells intact [27]. Since HER2 targeted therapies have shown indisputable 
clinical benefit in metastatic breast cancer [28], we generated a recombinant baculovirus displaying 
anti-HER2 scFv expressing cytotoxic protein Apoptin was generated. We demonstrated that  ourThis 
recombinant BV is able to selectively targets the HER2 positive breast cancer cell line SK-BR-3 
(Figure. 6) and reduced its cell viability by expressing Apoptin (Figure. 8A,BA, B) but not in the 
HER2 negative MCF-7 breast cancer cell line. 
Baculovirus display technology previously showed that has advantages in the target therapy 
applicationhas previously been shown to have been employed with regard to targeted cancer therapy. 
Baculovirus vector displaying scFv-CEA (Carcino Embryonic Antigen) fusion to GP64 showed a 
binding specificity to CEA- expressing cells [29]. Different strategies for the fusion of a foreign 
protein or peptide to the baculovirus envelope, including fusion to GP64 and VSV-G glycoprotein, 
hasve been proposed [13]. In order to conquer the limitation of these strategies which restrict the 
display to the poles of the virions, Kitidee et aland colleagues demonstrated that fusion of an 
octadecapeptide sequence N18E2 (MEASLAAQAAQIQLVQSG), which mediatesd the anchoring of 
scFv into the baculoviral envelope, to the N-terminus of scFv molecules of interest could be applied 
for BV display [13]. 
In our this study,  we used the N18E2 sequence was used, 18 amino acids 
(MEASLAAQAAQIQLVQSG) sequence in the N- terminus of anti-HER2 scFv for displaying the 
scFv on the BV’s envelope. As shown in the fig Figure 5A gold particles attached to the surface of 
recombinant BV-displayed anti-HER2 scFv. Our findings in corroborate with the findings by Kitidee 
et aland colleagues resultswhich demonstrated that this strategy can be used for displaying the scFv on 
the surface of BV [13]. Moreover, immunofluorescence analysis showed that anti-HER2 scFv was 
expressed on the recombinant BV in comparewhislt no such expression was seen with PBS and BV-
control (Figure 4), consistent with in corroborate with electron microscopy results (Figure 5). Binding 
specificity and efficient display of anti-HER2 scFv on the BV surface was confirmed by ELISA 
(Figure 3A, 3-B). These data suggested indicated proper display of that anti-HER2 scFv properly 
displayed on the BV surface.  
Gene therapy has become an attractive strategy for the cancer treatment in recent years, with the use 
of . Whereas baculoviruses has demonstrating several potential advantages over other vectors in this 
field [30]. For the first time, Hofmann and colleagues demonstrated that the baculovirus has the 
ability as a vector to deliver sustainable foreign genes expression in human hepatocytes in 1995 [31]. 
Since then, BV has shown to be capable of transducing a wide range of mammalian cells and has been 
used as a gene therapy vector in a preclinical studies [32-35].  
In the current study, we demonstratedit was demonstrated that BV-displaying anti-HER2 scFv could 
specifically bind to HER2-overexpressing SK-BR-3 cells but not to the HER2 negative MCF-7 cells 
(Figure 6). In addition, our the results showed that this targeting activity is in a dose- dependent 
manner and abundant expression of GFP at an MOI 200 after transduction with BV- anti-HER2 scFv 
confirmed the targeting of HER2- positive breast cancer cells (Figure 6). This finding is in accordance 
with reports that from Li et aland colleagues in 2001. They demonstrated that a non-viral vector 
carrying anti-ErbB2 scFv (ScFv-P-S) can selectively targeteds the ErbB2(+) cells with an 8 to 10 fold 
increase in luciferase reporter gene expression levels in compared withcompared to ErbB2(-) cells 
[36]. In another study, Zhao and his colleagues generated the expression vector pCMV-e23sFv-PE II 
GrBa which was able to selectively identifyfied and destroyed SKBR-3 cells which expressed higher 
levels of HER2 [37]. 
Other works have used anti-HER2 scFv antibody for targeting breast cancer cells using the Pichia 
pastoris as the host for the expression of antibody fragments [38] and developing anti-HER2 scFv–
HSA fusion antibodies conjugates with drug DM1 [39]. In a recent study, Alric and colleagues 
showed the specific binding and high affinity properties of SPIONs-Cy-PEG-scFv nanoparticles 
against HER2 positive breast cancer cells, leading to Alric and colleagues  and suggestingsuggesting 
the use of this nanoparticle as an imaging agents for the diagnosis of breast tumors with HER2 
overexpression [40]. ThereforeTherefore, novel therapeutic approaches which facilitate the selective 
targeting of breast cancer cells such as using viral vector displaying anti-HER2 scFv will be 
considered as a promising candidate for delivering genes to HER2 positive breast cancer cells. 
However, Apoptin has been shown to be able to induce the apoptosis in a variety of tumor cells [18], 
[18] and efficient delivery systems is are required to transfer Apoptin to cancer cells. Here we showed 
that the ability of BV-displaying anti-HER2 scFv to deliver Apoptin into breast cancer cells was 
demonstrated (Figure 7). Our The findings presented herein indicated that Apoptin protein was highly 
expressed in the SK-BR-3 HER2 positive breast cancer cell line. The lLow level of Apoptin 
expression in MCF-7 cells line may be explained by the low level of HER2 receptor at the MCF-7 
cells. This finding is in consistent with Alric and colleagues which showed 99% of SK-BR-3 cells 
highly expressed the HER2 receptors at the cell surface in compare withcompared to 26% of MCF-7 
cells. They also demonstrated that the uptake of nanoparticle SPIONs-Cy-PEG-scFv by breast cancer 
cells is related to level of HER2 expression. According to their finding the amount of SPIONs-Cy-
PEG-scFv able to penetrate the MCF-7 cells (considered as a HER2 negative) is very few in 
compared withcompared to high uptake in SK-BR-3 HER2 positive cell lines [40].  
To assess the cytotoxic effect of BV anti-HER2 scFv expressing Apoptin, SK-BR-3 and MCF-7 cells 
were treated with this vector. As shown in Figure 8A, 8-B the viability of SK-BR-3 breast cancer cells 
treated with BV anti-HER2 scFv expressing Apoptin significantly has reduced compared to MCF-7 
cells. Consistent with our these results Pan and colleagues developed a recombinant baculovirus 
expressing Apoptin and showed its antitumor effects in transduced HepG2 and H22 cells [9]. Several 
studies reported an antitumor effect of Apoptin in breast cancer cells. Shoae-Hassani and colleagues 
constructed a λ phage expressing the Apoptin which significantly inhibited growth of the various 
breast cancer cell lines in vitro [18]. AnoOther study also showed that HSA- mediated Apoptin 
infection was able to reduce the viability and induce the apoptosis in MCF- 7 cells [41]. In addition, 
our the results presented herein demonstrated that that BV anti-HER2 scFv expressing Apoptin 
specifically killed SK-BR-3 HER-2 breast cancer cells, while whilst it had low or no toxicity in MCF-
7 breast cancer cells. 
Conclusions 
The present study is the first effort for targeting HER2- positive breast cancer cells by anti-HER2 
scFv BV expressing Apoptin. Our This recombinant baculovirusconstruct resulted in the successful 
targeting of HER2-overexpressing SK-BR-3 cells. Furthermore, our the results showed that the 
viability of SK-BR-3 breast cancer cells treated with BV anti-HER2 scFv expressing Apoptin 
significantly has reducedwas significantly reduced compared to MCF-7 cells. Our The results suggest 
that, anti-tumor effect of Apoptin in combination with HER2 targeting of this recombinant BV makes 
it a promising vector not only in breast cancer therapy but also in other HER2 over expressing tumors 
[42]. 
The result of this study provides new insight into breast cancer target therapy. Further studies are 
needed with more breast cancer cell lines to reveal selective targeting of BV anti-HER2 scFv 
expressing Apoptin in HER2 positive cells.  Also, in vivo studies need to be done to assess the 
inhibition of tumor growth without affecting the normal tissue.  
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Future perspective  
 
The result of the present study shows that a combination of the anti-HER2 scFv targeting 
property with the cytotoxic effector Apoptin, is an applied approach for the treatment of 
HER2-positive breast tumors. In the first stage, this recombinant baculovirus showed the 
promising results in in vitro study. In the next stage, assessing the specific tumor-targeting 
property of this recombinant BV in normal human breast cells beside the other breast cancer 
cell lines is very useful. If this vector passes the preclinical animal studies, it could be 
employed in the clinical trial study. 
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Summary points 
EXECUTIVE SUMMARY 
Aim 
 Targeted cancer therapy is becoming important due to its specificity towards cancer cells whereas 
whilst leaving normal cells intact 
 This study aimed to generate a recombinant baculovirus displaying anti-HER2 scFv expressing 
Apoptin and we evaluatede its binding specificity and cytotoxicity to HER2-overexpressing SK-
BR-3 and MCF-7 breast cancer cell lines cells.  
 Materials & Methods 
 Recombinant baculoviruses were constructed according to the Bac-to-Bac expression system 
(Invitrogen) and expression of anti-HER2 scFv protein in Sf9 cells were evaluated by western 
blotting and immunofluorescence microscopy.  
 The binding specificity and surface display of anti-HER2 scFv was evaluated by ELISA and 
electron microscopy, respectively. 
  Targeting propertiesy of BV-displaying anti-HER2 scFv against HER2 positive SK-BR-3 breast 
cancer cells was determined by evaluating EGFP expression under the fluorescence microscopy.  
 Apoptin expression and its cytotoxic effect was evaluated in in SK-BR-3 and MCF-7 cells by 
western blotting and MTT assay. 
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 Results & conclusion 
 
 BV-displaying anti-HER2 scFv could specifically bind to HER2-overexpressing SK-BR-3 cells 
but not to the HER2 negative MCF-7 cells which have low HER2 expression.  
 The viability of SK-BR-3 breast cancer cells treated with BV anti-HER2 scFv expressing Apoptin 
significantly has reducedwas significantly reduced compared to MCF-7 cells.  
 These results suggest that, the anti-tumor effect of Apoptin in combination with HER2 targeting 
of this recombinant BV makes it a promising vector in targeted cancer therapy in HER2 over 
expressing tumors. 
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Supplementary Table 1 
 
 
  Name Sequence Direction Tm ℃ 
  
anti-HER2 
pFastBac1 
PVEC-F 5'-GCC CAG GAC TCT AGC TAT AGT TCT AGT-3' Forward 68 
PVEC-R 5'-ACT AGA TTT CAC TTA TCT GGT TCG G-3'  
  
Reverse 63 
PCMV-EGFP PCMV EGFP-F 5'-ATAGTAATCAATTACGGGGTCA-3' Forward 
  
68 
PCMV EGFP-R 5'-GCGCGGATCCTTACTTGTACAGCTCGTCC-3'  Reverse 65 
Apoptin VP3-F 5'- AAGCGCTAGCATGAATGCCCTTCA -3' Forward 
  
68 
VP3-R 5'- ACGTCCCGGGTTAAAGTCGTATCCTC -3' Reverse 67 
Recombinant 
BV 
PUC/M13-F 5′-CCCAGTCACGACGTTGTAAAACG-3′ Forward 
  
64 
PUC/M13-R 5′-AGCGGATAACAATTTCACACAGG-3 Reverse 61 
